Melanie Ivarsson Email Address

Vice President, Head of Clinical Operations

Moderna is pioneering messenger RNA Therapeutics, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 250 patent applications with more than 12,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugsinitially for rare diseases and oncologywhile partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts.

- Approximately 16 years experience in the operational and clinical aspects of exploratory drug development, ensuring optimal delivery of Phase 1/1b studies, including clinical pharmacology and translatable methodology studies and global patient studies (Phase 2) across multiple therapeutic areas - Established people manager with considerable experience of building high functioning teams and organisations, increasing engagement and retaining talent - Track record of successful delivery of project goals and process improvement implementation. Specialties: early phase drug development specialising in phase 1 and 2, clinical pharmacology, methodology studies, translatable sciences, people management